Desano Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 55.00 Cr
as on 17-07-2024
- Paid Up Capital ₹ 49.69 Cr
as on 17-07-2024
- Company Age 12 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 59.90%
(FY 2023)
- Ebitda -1.84%
(FY 2023)
- Net Worth -1.51%
(FY 2023)
- Total Assets 182.32%
(FY 2023)
About Desano Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 55.00 Cr and a paid-up capital of Rs 49.69 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Desano Pharmaceuticals Private Limited India is Kamath as COMPANY SECRETARY. Li Jingpeng and Sasikumar Kannaiyan serve as directors at the Company.
- CIN/LLPIN
U24233KA2012FTC130244
- Company No.
130244
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
19 Nov 2012
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bengaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Desano Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shreya Kamath | Company Secretary | 15-Jun-2023 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Li Jingpeng  | Director | 19-Nov-2012 | Current |
Sasikumar Kannaiyan  | Director | 15-Nov-2019 | Current |
Financial Performance of Desano Pharmaceuticals.
Desano Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 59.9% increase in profit. The company's net worth dipped by a decrease of 1.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Desano Pharmaceuticals?
In 2023, Desano Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Desano Pharmaceuticals?
Desano Pharmaceuticals has a workforce of 163 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Desano Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Desano Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
